Citations

Clear

361 citation(s) found for "Bauer, M".

Current trends in health coaching for chronic conditions
Yang, Juan , Bauer, Brent A. , Lindeen, Stephanie A. , Dabrh, Abd Moain Abu , Boehmer, Kasey R. , Salinas, Manisha , Cutshall, Susanne M. , Abu Dabrh, Abd Moain, Abu Dabrh, Abd Moain , Perlman, Adam

Mayo Clinic

Medicine | July 21, 2020 | Volume: 99 | Issue: 30 | Pages: e21080

10.1097/md.0000000000021080 | PMID 32791680 Get It

Abstract Background: Chronic conditions are placing a serious burden on individuals as well as the health care system. Health coaching (HC) has emerged as a promising approach that can support effective lifestyle interventions for chronic conditions. However, until now there is no particularly comprehensive systematic review of HC impact on a chronic condition from the angle of patient improvement and detail coaching characteristics reported. Objective: To synthesize available studies on the efficacy and current status of HC interventions on the health of chronically ill adult patients. Methods: The literature search will be conducted for trials published in English within the past four years. Electronic databases CINAHL, Cochrane Library, Embase, MEDLINE, and Scopus will be searched with keywords describing HC for chronic diseases. Randomized controlled trials that compare HC interventions to conventional care or other alternative therapies will be included. Data extraction will be conducted by two reviewers independently, and enrolled trials will be evaluated for quality and bias assessment. If appropriate, meta-analysis will be conducted on the last stage of the review; otherwise, the study findings will be described narratively. The software Review Manager (Revman version 5.3.5.) provided by the Cochrane Collaboration will be applied for the meta-analysis. Results: This is the first study to comprehensively explore the effectiveness and current status of HC intervention for patients with chronic conditions. Discussion: Study findings from this review will advance the appropriate utilization of coaching practice by determining whether HC is effective and feasible among patients with chronic disease. If proven effective, this approach may be applied more broadly through public health interventions. The current status findings will also provide evidence to inform decisions for integrating HC interventions into the current management pathway for individuals with chronic conditions. Systematic review registration: PROSPERO CRD42020153280.
Massage Compared with Massage Plus Acupuncture for Breast Cancer Patients Undergoing Reconstructive Surgery
Dilaveri, Christina A. , Croghan, Ivana T. , Mallory, Molly J., Dion, Liza J., Schroeder, Darrell R. , Martinez‐Jorge, Jorys, Nguyen, Minh-Doan T., Fokken, Shawn C. , Bauer, Brent A. , Wahner‐Roedler, Dietlind L. , Martinez-Jorge, Jorys, Wahner-Roedler, Dietlind L., Schroeder, Darrell , Fischer, Karen M. , Nguyen, Minh-Doan T.

Mayo Clinic

The Journal of Alternative and Complementary Medicine | July 16, 2020 | Volume: 26 | Issue: 7 | Pages: 602-609

10.1089/acm.2019.0479 | PMID 32673082 Get It

Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis
Wagner, Tyler , Shweta, Fnu , Awasthi, Samir , Bade, Sairam, Puranik, Arjun, Kang, Martin , Pickering, Brian W. , O’Horo, John C. , Vergidis, Paschalis , Temesgen, Zelalem , Rizza, Stacey A. , Mahmood, Maryam , Wilson, Walter R. , Liebers, Matt, Doctor, Zainab M., Silvert, Eli , Solomon, Hugo, Barve, Rakesh , Williams, Amy W. , Morice, William G. , Badley, Andrew D. , Venkatakrishnan, A J , O'Horo, John C, Rizza, Stacey , Challener, Douglas , Anand, Praveen , Badley, Andrew, Soundararajan, Venky , Badley, Andrew D , O'Horo, John C , Vergidis, Paschalis , Mahmood, Maryam , Shweta, Fnu , Wagner, Tyler, Murugadoss, Karthik , Bauer, Philippe R. , Razonable, Raymund R. , Challener, Douglas W. , Anand, Praveen , Anand, Akash, Gores, Gregory J. , Morice, William George , Halamka, John , Soundararajan, Venky

Mayo Clinic

eLife | July 7, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.58227 | PMID 32633720 Get It

Understanding temporal dynamics of COVID-19 symptoms could provide fine-grained resolution to guide clinical decision-making. Here, we use deep neural networks over an institution-wide platform for the augmented curation of clinical notes from 77,167 patients subjected to COVID-19 PCR testing. By contrasting Electronic Health Record (EHR)-derived symptoms of COVID-19-positive (COVID pos ; n = 2,317) versus COVID-19-negative (COVID neg ; n = 74,850) patients for the week preceding the PCR testing date, we identify anosmia/dysgeusia (27.1-fold), fever/chills (2.6-fold), respiratory difficulty (2.2-fold), cough (2.2-fold), myalgia/arthralgia (2-fold), and diarrhea (1.4-fold) as significantly amplified in COVID pos over COVID neg patients. The combination of cough and fever/chills has 4.2-fold amplification in COVID pos patients during the week prior to PCR testing, in addition to anosmia/dysgeusia, constitutes the earliest EHR-derived signature of COVID-19. This study introduces an Augmented Intelligence platform for the real-time synthesis of institutional biomedical knowledge. The platform holds tremendous potential for scaling up curation throughput, thus enabling EHR-powered early disease diagnosis.
Aminoglycosides in Immunocompromised Critically Ill Patients With Bacterial Pneumonia and Septic Shock: A Post-Hoc Analysis of a Prospective Multicenter Multinational Cohort
López, René , Salem, Omar Ben Hadj , Seguin, Amélie, Louw, Andry Van de , Klouche, Kada , Martín‐Loeches, Ignacio , Mehta, Sangeeta , Bruneel, Fabrice , Lisboa, Thiago , Viana, William, Pickkers, Peter, Russell, Lene , Rusínová, Kateřina , Kouatchet, Achille, Barbier, François , Russell, Lene , Martin-Loeches, Ignacio , Rello, Jordi , Taccone, Fabio Silvio , Bauer, Philippe R. , Metaxa, Victoria , Montini, Luca , Mokart, Djamel , Azoulay, Élie , Darmon, Michaël

Mayo Clinic

Shock | June 3, 2020 | Volume: 54 | Issue: 6 | Pages: 731-737

10.1097/shk.0000000000001553 | PMID 32496415 Get It

ABSTRACT Background: The routine use of empiric combination therapy with aminoglycosides during critical illness is associated with uncertain benefit and increased risk of acute kidney injury. This study aimed to assess the benefits of aminoglycosides in immunocompromised patients with suspected bacterial pneumonia and sepsis. Methods: Secondary analysis of a prospective multicenter study. Adult immunocompromised patients with suspected bacterial pneumonia and sepsis or septic shock were included. Primary outcome was hospital mortality. Secondary outcomes were needed for renal replacement therapy (RRT). Mortality was also assessed in neutropenic patients and in those with confirmed bacterial pneumonia. Results were further analyzed in a cohort matched on risk of receiving aminoglycosides combination. Results: Five hundred thirty-five patients were included in this analysis, of whom 187 (35%) received aminoglycosides in addition to another antibiotic effective against gram-negative bacteria. Overall hospital mortality was 59.6% (58.3% vs. 60.3% in patients receiving and not receiving combination therapy; P = 0.71). Lack of association between mortality and aminoglycosides was confirmed after adjustment for confounders and center effect (adjusted OR 1.14 [0.69–1.89]) and in a propensity matched cohort (adjusted OR = 0.89 [0.49–1.61]). No association was found between aminoglycosides and need for RRT (adjusted OR = 0.83 [0.49–1.39], P = 0.477), nor between aminoglycoside use and outcome in neutropenic patients or in patients with confirmed bacterial pneumonia (adjusted OR 0.66 [0.23–1.85] and 1.25 [0.61–2.57], respectively). Conclusion: Aminoglycoside combination therapy was not associated with hospital mortality or need for renal replacement therapy in immunocompromised patients with pulmonary sepsis.
Impact of herbs and dietary supplements in patients with fibromyalgia
Yang, Juan , Bauer, Brent A. , Wu, Qinglong , Xiong, Donglin, Wahner‐Roedler, Dietlind L. , Chon, Tony Y. , Ganesh, Ravindra , Ganesh, Ravindra

Mayo Clinic

Medicine | May 28, 2020 | Volume: 99 | Issue: 21 | Pages: e20257

10.1097/md.0000000000020257 | PMID 32481303 Get It

Abstract Background: Fibromyalgia (FM) is a common chronic pain condition that seriously affects the quality of patient lives. Its etiology, pathogenesis, and treatment still remain uncertain. Dietary supplements have been widely trialed for symptom relief for FM. The review aims to synthesize the previous literature publications to assess the impact of herbs and dietary supplements on FM patients. Methods: We will conduct a literature search in the following databases PubMed, MEDLINE, EMBASE, Cochrane Library, Scopus, and Global Health from database inception to December 2019. Clinical studies published in the English language that used human participants and address the efficacy, safety, and acceptability of herbs and dietary supplements on individuals with FM will be included. The risk of bias and quality assessment of each trial will be evaluated. If trials are enough, a meta-analysis will be conducted using software RevMan5.3, Cochrane Collaboration. Result: Our review will be the first attempt to facilitate evidence-based management using herbs and dietary supplements to treat patients with FM. Conclusion: The findings may provide a framework for future research and clinic practice in FM management. PROSPERO registration number: CRD42020149941
The Safety of Laser Acupuncture: A Systematic Review
Yang, Juan , Mallory, Molly J., Wu, Qinglong , Bublitz, Sara E. , Do, Alexander , Xiong, Donglin, Chen, Christina Ying Ying, Dorsher, Peter T. , Chon, Tony Y. , Bauer, Brent A.

Mayo Clinic

Medical Acupuncture | May 27, 2020 | Volume: 32 | Issue: 4 | Pages: 209-217

10.1089/acu.2020.1419 | PMID 32874405 Get It

Objective: Laser acupuncture has become increasingly attractive in clinical practice, especially for patients with needle phobias well as elderly people and children. However, literature concerning the safety of laser acupuncture has been limited. This systematic review synthesizes the current available literature on the safety of laser acupuncture. Methods: Ovid MEDLINE, ® Epub Ahead of Print, In-Process & Other Non-Indexed Citations Daily, Ovid Embase, Scopus, and EBM Reviews—Cochrane Central Register of Controlled Trials databases were searched for available randomized controlled trials (RCTs) on laser acupuncture. Safety data were extracted from the included studies. Adverse events (AEs) data were extracted and assessed in terms of severity and causality. Results: Of 737 articles, 21 RCTs were included. The majority of these RCTs reported that laser acupuncture was safe, without AEs; 6 trials reported AEs (including tingling, pain flare-ups, and transient fatigue). All AEs were mild and resolved spontaneously within 24 hours. The causal relationship between AEs and laser acupuncture was felt to be “certain” in 4 studies, “probable” in 1 study, and “possible” in 1 study. AEs were collected and monitored by evaluation methods in 7 trials: 5 with AE questionnaires, 1 with a checklist, and 1 with oral reports. Conclusions: Laser acupuncture appears to be a safe therapy associated with few mild and transient AEs. However, given the heterogeneity of current studies, large, well-designed placebo-controlled RCTs with rigorous evaluation methods are needed to assess the safety of laser acupuncture more completely.
Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.
Schöffski, Patrick , Attia, Steven , D’Amato, Gina Z. , Reichardt, Peter , Cha, Elva, Meade, Julie Nicole, Ruiz‐Soto, Rodrigo , George, Suzanne , Heinrich, Michael C. , Zalcberg, John , Bauer, Sebastian , Gelderblom, Hans , Serrano, César , Jones, Robin L. , Chi, Ping , Lacouture, Mario E. , Blay, Jean‐Yves , Mehren, Margaret von

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 11539-11539

10.1200/jco.2020.38.15_suppl.11539 Get It

11539 Background: Ripretinib is a novel switch-control TKI that broadly inhibits KIT and PDGFRA kinase signaling. In INVICTUS (NCT03353753), a randomized, double-blind, placebo (PBO)-controlled trial of ripretinib in ≥4th-line advanced GIST, ripretinib reduced the risk of disease progression or death by 85% vs PBO with a favorable overall safety profile. Common ( > 20%) adverse events (AEs) included, but were not limited to, alopecia and PPES. Exploratory analyses evaluated the impact of alopecia and PPES on quality of life (QoL). Methods: Patients (pts) with advanced GIST previously treated with at least imatinib, sunitinib, and regorafenib were randomized (2:1) to ripretinib 150 mg QD or PBO. AEs were graded using CTCAE v4 and PROs collected using EQ-5D-5L (EQ5D) and EORTC QLQ-C30 (C30). Repeated measures (RM) models assessed the impact of alopecia and PPES on 5 PROs (EQ5D visual analogue scale; and C30 physical functioning, role functioning, and the overall health and overall QoL questions) within the ripretinib arm. Fixed effects were sex, alopecia/PPES, and ECOG scores at baseline. Results: 128/129 randomized pts received treatment (85 ripretinib 150 mg QD; 43 PBO). Alopecia, regardless of causality, occurred in 44 (51.8%) on ripretinib (34 [40.0%] grade 1; 10 [11.8%] grade 2) and 2 (4.7%) on PBO (both grade 1). PPES occurred in 18 (21.2%) on ripretinib (11 [12.9%] grade 1; 7 [8.2%] grade 2); none on PBO. The median times in days to first occurrence and worst severity grade with ripretinib were 57.0 and 62.5 for alopecia; 56.5 and 57.0 for PPES. The RM models showed a slight trend towards improvement in PRO score over time for pts with alopecia; the only association reaching a P-value of < 0.05 was between alopecia and increased overall QoL. None of the associations between PPES and PRO scores reach P < 0.05. All PRO p-values are nominal, and no statistical significance is being claimed. Conclusions: Ripretinib had a favorable overall safety and tolerability profile. When stratified by alopecia and PPES, patient-reported assessments of function, overall health, and overall QoL were maintained over time. For both alopecia and PPES, onset and maximum severity occurred almost simultaneously, indicating that these events generally did not progressively worsen. These results suggest that alopecia and PPES are manageable and do not have a negative effect on function, overall health, and QoL. Clinical trial information: NCT03353753 .
Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.
Schöffski, Patrick , Serrano, C Pardo, Attia, Steven , D’Amato, Gina Z. , Reichardt, Peter , Becker, Claus, Meade, Julie Nicole, Ruiz‐Soto, Rodrigo , Heinrich, Michael C. , George, Suzanne , Zalcberg, John , Bauer, Sebastian , Gelderblom, Hans , Jones, Robin L. , Chi, Ping , Mehren, Margaret von , Blay, Jean‐Yves

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 11535-11535

10.1200/jco.2020.38.15_suppl.11535 Get It

11535 Background: Ripretinib is a novel switch-control tyrosine kinase inhibitor (TKI) that broadly inhibits KIT and PDGFRA kinase signaling through a dual mechanism of action. In INVICTUS (NCT03353753), a randomized, double-blind, placebo-controlled trial of ripretinib in ≥4th-line advanced GIST, ripretinib reduced the risk of disease progression or death by 85% vs placebo and had a favorable overall safety profile in patients previously treated with ≥3 prior TKIs. Methods: As part of the INVICTUS trial, patient reported outcome (PRO) measures were collected using EQ-5D-5L (EQ5D) and EORTC QLQ-C30 (C30). In prespecified and additional analyses, ANCOVA models were built to compare changes from baseline to cycle 2 day 1 (C2D1) for PRO measures within the ripretinib and placebo arms and determine the difference between treatment arms. PRO measures included the EQ5D visual analogue scale (VAS) and the C30 physical functioning (PF) and role functioning (RF) scales (all scores range from 0–100; higher scores are better). The C30 overall health and overall QoL questions were also assessed (scores range from 1–7; higher scores are better). Fixed effects included treatment arm, number of previous anticancer treatments (3 vs ≥4), and ECOG score at baseline (0 vs 1/2). Results: Overall, 129 patients were randomized and 128 received treatment (85 to ripretinib 150 mg QD; 43 to placebo). All PRO p-values are nominal, and no statistical significance is being claimed. VAS scores improved an average 3.7 points from baseline to C2D1 with ripretinib vs an average decline of 8.9 with placebo (P = 0.004; improvement or no change, 67% vs 41% of patients, respectively). Similarly, the average PF score improved 1.6 points with ripretinib and decreased 8.9 with placebo (P = 0.004; improvement or no change, 68% vs 44%). RF scores also improved an average of 3.5 points with ripretinib vs a decrease of 17.1 with placebo (P = 0.001; improvement or no change, 77% vs 50%). For the overall health and overall QoL questions, scores increased with ripretinib an average of 0.20 and 0.28, respectively, and decreased 0.78 and 0.76 with placebo (both P = 0.001; improvement or no change, 74% vs 47% and 79% vs 59%, respectively). Conclusions: Based on the 5 PRO measures assessed, when compared with placebo and best supportive care, ripretinib provided patient-benefit in advanced GIST with PRO measures of role and physical function, VAS, overall health, and overall QoL remaining stable. Clinical trial information: NCT03353753 .
Osteoporosis Management in the Era of COVID-19
Yu, Elaine W , Clarke, B.L. , Bauer, Douglas C. , Drake, Matthew T. , Clarke, Bart L , Bauer, Douglas C , Drake, Matthew T , Tsourdi, Elena

Mayo Clinic

Journal of Bone and Mineral Research | May 14, 2020 | Volume: 35 | Issue: 6 | Pages: 1009-1013

10.1002/jbmr.4049 | PMID 32406536 Get It

ABSTRACT Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture. As a chronic condition, osteoporosis generally requires sustained medical intervention(s) to limit the risks for additional bone loss, compromise of skeletal integrity, and fracture occurrence. Further complicating this issue is the fact that the abrupt cessation of some therapies can be associated with an increased risk for harm. It is in this context that the COVID-19 pandemic has brought unprecedented disruption to the provision of health care globally, including near universal requirements for social distancing. In this Perspective, we provide evidence, where available, regarding the general care of patients with osteoporosis in the COVID-19 era and provide clinical recommendations based primarily on expert opinion when data are absent. Particular emphasis is placed on the transition from parenteral osteoporosis therapies. It is hoped that these recommendations can be used to safely guide care for patients with osteoporosis until a return to routine clinical care standards is available. © 2020 American Society for Bone and Mineral Research.
Physiological State of Therapy Dogs during Animal-Assisted Activities in an Outpatient Setting
Clark, Stephanie , Martin, François , McGowan, Ragen T. S. , Smidt, Jessica M., Anderson, Rachel , Turpin, Tricia, Langenfeld-McCoy, Natalie, Bauer, Brent A. , Mohabbat, Arya B. , Clark, Stephanie D, Mohabbat, Arya B , Wang, Lei

Mayo Clinic

Animals | May 11, 2020 | Volume: 10 | Issue: 5 | Pages: 819

10.3390/ani10050819 | PMID 32397366 Get It

Therapy dogs are increasingly being incorporated into numerous clinical settings. However, there are only a handful of studies that have focused on the impact of animal-assisted activity or therapy sessions on the wellbeing of the therapy dogs. Furthermore, these studies show mixed results. The goal of this study was to provide an in-depth picture of the effects of these interactions on the dogs involved by considering multiple physiological measures known to be associated with emotional state (continuous heart rate, heart rate variability, pre- and post-session tympanic membrane temperatures, and salivary cortisol and oxytocin concentrations). Nineteen Mayo Clinic Caring Canine therapy dogs completed five 20-minute animal-assisted activity (AAA) visits each in an outpatient clinical setting (Mayo Clinic Fibromyalgia and Chronic Fatigue Clinic). From a physiological perspective, the dogs showed a neutral to positive response to the AAA sessions. Heart rate (HR) was significantly lower at the end of the session compared with the beginning of the session (F = 17.26, df1 = 1, df2 = 29.7, p = 0.0003). The right tympanic membrane temperature was lower post-session (F = 8.87, df1 = 1, df2 = 107, p = 0.003). All other emotional indicators remained stable between pre- and post-session. These results suggest that the dogs involved were not negatively affected by their participation in the AAA. Moreover, there was some evidence suggesting the dogs may have been in a more relaxed state at the end of the session (lower HR and lower right tympanic membrane temperature) compared to the beginning of the session.